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Abstract
Objectives—Hemoglobin A1c levels <7.0% and systolic blood pressure (SBP) <140mmHg are 
each associated with lower risk of vascular complications in patients with diabetes mellitus. 
Association between combined A1c level and SBP categories and risk of mortality and morbidity 
in diabetic patients are not well characterized.
Methods—We examined 891,670 US diabetic veterans with baseline eGFR >60ml/min/1.73m2 
(mean age 67±11 years, 97%males, 17% African-Americans). The association of mutually 
exclusive combined categories of A1c (<6.5, 6.5–6.9, 7.0–7.9, 8.0–8.9, 9.0–9.9, and ≥10%) and 
SBP (<100, 100–119, 120–139, 140–159, 160–179, and ≥180mmHg) with the risk of all-cause 
mortality and incident chronic kidney disease (CKD), coronary heart disease (CHD), and stroke 
was examined in Cox models adjusted for baseline characteristics using patients with concomitant 
A1c 6.5–6.9% and SBP of 120–139 mmHg as the referent group.
Results—A total of 221,529 (25%) patients died, and 178,588 (20%), 43,373 (5%) and 36,935 
(4%) developed CKD, CHD and stroke, respectively, during a median follow-up of 7.4 years. SBP 
displayed a J-shaped association with each outcome except CKD risk that was linearly associated 
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with SBP across all A1c categories. A1c above 7.0% was associated with monotonically worse 
outcomes for all end points in all SBP categories. Patients with the combined highest A1c and 
SBP levels experienced the worst outcomes.
Conclusion—Systolic BP >120–139mmHg and A1c >7.0% are associated with higher mortality 
and vascular complications in diabetic patients, independent of each other. Combined efforts to 
improve both glycemic and BP control may synergistically improve outcomes in patients with 
normal kidney function.
Keywords
Hemoglobin A1c; systolic blood pressure; morbidity; mortality
Introduction
Preventing vascular complications and reducing mortality is critical to the chronic 
management of diabetes mellitus in clinical practice. Comprehensive diabetes management 
programs should target the achievement of several goals [1]. Reducing glycated hemoglobin 
unequivocally diminishes the risk of microvascular complications of diabetes including the 
development of diabetic nephropathy [2–5]. On the other hand, the immediate 
macrovascular benefits of glycemic control were not as prominent across landmark diabetes 
trials [6] although recent reports demonstrated long-term cardiovascular benefits from 
intensive glycemic control in type 2 diabetes [7]. Despite vascular risk reduction, strict 
glycemic control had neutral or modest mortality benefits in some studies and harmful 
effects in the intensive arm of the Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial [6].
Hypertension is highly prevalent in patients with diabetes mellitus. Up to 75% of diabetics 
may have elevated blood pressure requiring pharmacological therapy [8]. The UK 
Prospective Diabetes Study (UKPDS) showed that blood pressure control in type 2 diabetes 
reduces the risk of vascular complications including cardiovascular disease and mortality 
[9]. The lower bound for optimal blood pressure reduction in diabetics was unclear until the 
ACCORD investigators showed that a systolic blood pressure target between 120–140 
mmHg seems most optimal for the majority of patients [10]. Hence, it might be clinically 
strategic to target both hyperglycemia and hypertension in an attempt to achieve even better 
vascular and mortality outcomes.
Multifactorial risk factor modification in diabetes patients with microalbuminuria that 
simultaneously targets glycemia, blood pressure and lipids can offer additional 
cardiovascular morbidity and mortality benefits beyond the effects of individual risk factor 
modification [11, 12]. Observational analyses of the UKPDS suggested additive 
cardiovascular (CV) benefits from intensive control of both hyperglycemia and hypertension 
[13]. However, recent analyses from the interventional ACCORD study did not demonstrate 
additive cardiovascular benefits from a simultaneous strategy of both intensive glycemic and 
blood pressure control compared with the effects of each arm alone in type 2 diabetes 
patients with normal renal function [14]. In contrast, the subgroup analyses of the Action in 
Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation 
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(ADVANCE) trial demonstrated that, compared with each arm alone, combination of routine 
blood pressure lowering and intensive glucose control produced additional reductions in new 
onset diabetic nephropathy risk and mortality [15].
With these variable findings in macrovascular and mortality outcomes across glycemic trials 
and trends towards additional vascular and mortality benefits from combined intensive 
glycemic and blood pressure control studies, it remains unknown as to whether there is a 
specific threshold at which glycemia and hypertension control would complement each other 
multiplicatively in chronic diabetes management, or if extremes of each risk factor might 
mitigate or enhance the benefits of controlling the other. The aim of this study was to 
investigate the impact of combined glycemic and blood pressure level on the risk of all-
cause mortality, coronary heart disease, stroke, and chronic kidney disease in patients with 
normal kidney function at baseline.
Methods
Clinical and demographic measures
The institutional review committees at the Memphis and Long Beach Veterans Affairs 
Medical Centers approved the study. Our study utilized data from a cohort study examining 
risk factors in patients with incident chronic kidney disease (CKD) (Racial and 
Cardiovascular Risk Anomalies in CKD (RCAV) study) [16]. We used the national Veterans 
Affairs (VA) Labchem file to extract data on serum creatinine and to identify veterans with 
normal kidney function on the basis of estimated glomerular filtration rates (eGFRs) of ≥60 
ml/min/1.73m2 [17]. eGFR was calculated according to the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) Equation [18]. We identified 3,582,478 patients 
with eGFR ≥60 ml/min/1.73m2 among a total of 4,444,699 patients with any available eGFR 
between October 1, 2004 and September 30, 2006. The algorithm for the cohort definition is 
shown in Figure 1. Diabetes mellitus was defined by ICD-9 codes, HbA1c >6.4% or based 
on the prescription of one or more hypoglycemic agents in the outpatient setting during the 
baseline period (October 1, 2004–September 30, 2006), based on information obtained from 
VA Pharmacy dispensation records. Hypertension was defined by ICD-9 codes during the 
baseline period. The final cohort included 891,670 patients who had both diabetes and 
hypertension.
Socio-demographic characteristics, comorbid conditions (Table S1) and laboratory 
characteristics were obtained as previously described [19–22]. Briefly, baseline information 
about age, gender, race, systolic blood pressure (SBP) and hemoglobin A1c (A1c) were 
obtained through the VA Corporate Data Warehouse (CDW) and from Medicare through the 
VA-Medicare data merge project. Comorbidity information was collected from the VA 
Inpatient and Outpatient Medical SAS Datasets using ICD-9-CM diagnostic and procedure 
codes during the baseline period. We divided patients into 36 a priori defined mutually 
exclusive categories based on combined baseline A1c and baseline SBP values: A1c levels 
<6.5, 6.5–6.9, 7.0–7.9, 8.0–8.9, 9.0–9.9, and ≥10% and SBP levels <100, 100–119, 120–
139, 140–159, 160–179, and ≥180mmHg, respectively. The group with A1c level 6.5–6.9% 
and SBP level 120–139 mmHg was used as the reference group in our analysis.
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Assessment of outcomes
We defined four different outcomes: 1) all-cause mortality, 2) incident coronary heart 
disease (CHD), 3) incident ischemic stroke, and 4) incident CKD. Data on all-cause 
mortality was obtained from the VA Vital Status Files (VSF), which contains dates of death 
or last medical/administrative encounter from all sources in the VA system with sensitivity 
and specificity of 98.3% and 99.8%, respectively, as compared to the National Death Index 
as gold standard [23]. Incident CHD was defined as the composite outcome of a first 
occurrence of an ICD-9-CM or CPT code for acute myocardial infarction, coronary artery 
bypass grafting, or percutaneous angioplasty after October 1, 2006 in patients without such 
diagnoses prior to this date. Incident stroke was defined as the first occurrence of ICD-9-CM 
codes for ischemic stroke after October 1, 2006 in patients without such diagnoses prior to 
this date (Table S2–S3). Incident CKD was defined as two consecutive eGFR levels <60 
ml/min/1.73m2 separated by ≥90 days, and a >25% decrease from baseline eGFR [24].
The start of the follow-up period for mortality and incident CKD analyses was the date of 
the first eGFR ≥60 ml/min/1.73m2 during October 1, 2004–September 30, 2006. Patients 
were followed until death or development of incident CKD, or were censored at the date of 
last healthcare or administrative visit, or on July 26, 2013.
In incident CHD and stroke analyses, incident CHD and stroke events were identified in 
patients without such diagnoses prior to October 1, 2006; therefore, to avoid immortal time 
bias [25] the start of the follow-up period for these end points was October 1, 2006. Patients 
were followed until the first incident CHD/stroke event or were censored at the date of 
death, last healthcare or administrative visit, or on July 26, 2013.
Statistical Analysis
Data were summarized using proportions, means ± SD, or medians (interquartile ranges 
(IQR)) as appropriate. The associations between the combined A1c and SBP groups and 
outcomes were assessed using crude and multivariable adjusted Cox proportional hazard 
models. Models were adjusted for the following confounders based on a priori 
considerations: age, gender, race/ethnicity, baseline eGFR, various socio-economic 
parameters (income, marital status, service connection, adherence to medical interventions 
(defined as the presence of the ICD9-CM code V15.81 during any inpatient or outpatient 
encounter), comorbidities (cardiovascular disease, congestive heart failure, cerebrovascular 
disease, peripheral vascular disease, lung disease, malignancy and depression), body mass 
index (BMI) and statin treatment during baseline. We performed subgroup analyses by age 
and by race for all outcomes. Statistical analyses were performed using Stata MP version 12 
(Stata Corporation, College Station, TX).
Results
Baseline Characteristics
The mean age of the cohort was 67±11 years, 97% were males, and 17% were African 
American. Baseline characteristics of the overall cohort categorized by A1c and SBP 
categories are shown in Table 1A–B. The mean A1c, SBP and BMI were 7.4±3%, 138±20 
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mmHg and 31.6±6 kg/m2, respectively. Patients with well-controlled diabetes defined by 
A1c of 6.5–6.9% were older and more likely to be married. During a median follow-up of 
7.4 years, 221,529 (25%) patients died, and 178,588 (20%), 43,373 (5%) and 36,935 (4%) 
developed CKD, CHD and stroke, respectively.
Association of blood pressure and glucose levels with mortality
The adjusted mortality hazard ratios (HRs) associated with the combined A1c and SBP 
categories are shown in Figure 2. There was a J-shaped relationship between A1c and 
mortality in each category of SBP. Similar J-shaped associations were observed between 
SBP and mortality in each A1c category. The highest risk of death was observed in 
individuals with a combination of A1c of ≥10% and SBP of <100mmHg or >180mmHg 
with adjusted HRs of 2.27 (95% confidence interval (CI): 2.01–2.57) and 2.07 (95%CI: 
1.91–2.23), respectively. In subgroup analyses, the combined effects of A1c and SBP on the 
risk of death were similar regardless of age or race (Supplementary Figure 1).
Association of blood pressure and glucose levels with incident macro- and microvascular 
events
For both incident CHD and stroke, we found a J-shaped association with SBP levels across 
all A1c categories (Figure 3A–B and Supplementary Table 4). Conversely, higher A1c levels 
were associated with a monotonic increase in risk of CHD and stroke in each SBP category. 
The lowest CHD and stroke risks were observed with A1c of <6.5% combined with systolic 
BP of 100–139mmHg. The highest risk of both macrovascular events was observed with 
A1c >10% combined with SBP of >180 mmHg (adjusted HR: 2.99, 95%CI: 2.58–3.48 for 
stroke and adjusted HR: 2.49, 95%CI: 2.11–2.94 for CHD).
Higher A1c levels were associated with higher risk of incident CKD in all SBP categories 
(Figure 3C). In contrast, we observed J-shaped associations with SBP categories in patients 
with A1c levels ≥6.5–7.0%, and a linearly higher risk associated with higher SBP in patients 
with A1c <6.5%. The lowest risk of incident CKD was observed in patients with A1c <6.5% 
combined with SBP of <100 mmHg (adjusted HR: 0.84, 95%CI: 0.72–0.98). The highest 
risk of incident CKD was associated with A1c >10% combined with SBP of >180 mmHg 
(adjusted HR: 2.70, 95%CI: 2.39–3.06).
In subgroup analyses, the association of A1c and SBP combinations with the risk of CHD, 
stroke and CKD were consistent with the primary analyses regardless of age or ethnicity 
(Supplementary Figures 2–4).
Discussion
There is consensus that the majority of diabetic patients should achieve treatment target 
goals of A1c <7.0% with avoidance of hypoglycemia and SBP <140mmHg while refraining 
from reduction to <120mmHg [1]; however, no prior studies have ascertained the combined 
effects of inadequate glycemic and hypertension control on mortality and morbidity in 
diabetes patients. We observed that, in patients with diabetes and normal renal function, SBP 
below and above the recommended range of 120–139 mmHg was associated with an 
increased hazard of all-cause mortality and nonfatal vascular outcomes across all ranges of 
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glycated hemoglobin. Our results also suggest that diabetes metrics of A1c and SBP above 
the recommended goals are associated with increased mortality and incident vascular events, 
and patients with diabetes may derive continuous and additive health benefits from 
optimizing both glycemic and blood pressure levels.
Many patients with diabetes are not achieving therapeutic targets that are proven to lower the 
incidence of vascular disease and are associated with reduction in mortality [26, 27]. Only 
about half of the patients with diabetes are able to achieve the benchmark goals of A1c and 
blood pressure control [27]. Although current success rates for A1c and blood pressure 
control have improved over the decades [26], there has been little reduction in the prevalence 
of stroke and end stage renal disease in the diabetes population [28]. With the marked 
economic burden of diabetes in society and the continuous search for opportunities to 
improve healthcare expenditures, recent evidence indicates that achieving LDL-cholesterol 
goals in addition to A1c management have even more profound clinical and economic 
benefits, compared to controlling either goal in isolation [29, 30]. To the best of our 
knowledge, there have been no similar attempts to assess the impact of combined glycemic 
and BP control in diabetics.
In our large cohort of the US veterans who were followed for about 7 years, we found a J-
shaped association between mortality and A1c and SBP categories. These data are in 
accordance with the results of previous studies and expert recommendations that targeting 
glycemic and blood pressure to the levels below or above the suggested goals is associated 
with an increased risk of mortality and vascular morbidity [2, 31, 32]. Our findings 
demonstrate potential additive effects of uncontrolled glycemia and hypertension on the risk 
of all-cause mortality and vascular outcomes. Prior studies suggested that in healthy non-
diabetic non-hypertensive men elevated baseline plasma glucose predicted development of 
future hypertension [33]. Whether more aggressive blood glucose lowering in patients with 
normotension or hypertension can result in better blood pressure control independent of use 
of anti-hypertensive agents deserves future investigation.
We showed higher risk of newly diagnosed CHD and stroke for those diabetes patients 
whose A1c and SBP control were below or above the recommended targets of 6.5–7.0% and 
120–139 mmHg, respectively. While earlier analyses from the prospective observational 
UKPDS [13] and randomized controlled ADVANCE [15] trials suggested additive and 
independent effects of hyperglycemia and hypertension on mortality and microvascular 
complications, most recent reports from ACCORD did not support such interaction between 
A1c and blood pressure control on outcomes in long-term diabetes management [3, 14]. Our 
results demonstrate a continuous additive effect of A1c and SBP below and above the 
recommended goals on mortality and macrovascular complications in a large, unselected 
diabetic population with hypertension, and support current recommendations towards 
optimization of both parameters. In non-diabetic patients with high baseline cardiovascular 
risk, SPRINT (Systolic Blood Pressure Intervention Trial) investigators have addressed 
benefits of blood pressure lowering below accepted targets [34]. The trial was terminated 
earlier than planned due to significant reduction of fatal and non-fatal major cardiovascular 
events and death from any cause in the arm assigned to a systolic blood pressure lowering of 
less than 120 mmHg.
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In our diabetes cohort with normal renal function, there was a linear association between 
glycemic and blood pressure categories and incident CKD. These findings could emphasize 
the importance of glycemic and hypertension control as a primary prevention measure for 
CKD. Conversely, the low incidence of CKD in the group with the lowest SBP could be 
affected by a competing risk of higher mortality associated with lower SBP, which was also 
shown in earlier results in veterans with established CKD [35, 36]. Future research should 
address the potential increased risks of mortality and macrovascular disease versus potential 
renal benefits in the process of achieving tight diabetic and blood pressure metrics.
It is noteworthy that the outcomes of our study reflect clinical behavior of providers who 
belong to a single payer system characterized by system-wide recommendations on 
achieving benchmark diabetes metrics. In our study of veterans with normal renal function, 
299,104 (34%) and 165,117 (19%) veterans achieved A1c levels of <6.5% and 6.5–6.9%, 
respectively and 368,911 (41%) reached a SBP of 120–139 mmHg. Combined A1c <7.0% 
and SBP of 120–139 mmHg were seen in 193,485 (22%) of our cohort. The attainment of 
A1c goals in our cohort composed of mostly older men with significant numbers of co-
morbid conditions mirrors nation-wide trends in improvement of glycemic control while our 
study findings regarding achievement of systolic blood pressure targets are slightly different 
compared to the recently published diabetes management metrics from community-based 
studies generally comprised of younger individuals, a greater proportion of women, and 
individuals with fewer comorbidities [26, 27].
With increasing prevalence of diabetes among the elderly, we performed subgroup analyses 
in patients who were 65 years old and older. We did not detect effect modification by age in 
the association of glycemic and blood pressure parameters with the risk of mortality and 
morbidity in diabetes. Also, several studies demonstrated ethnic/racial disparities in 
cardiovascular risk factor control in diabetes [27, 28, 37]. In our subgroup analyses, there 
was no difference in mortality risk and incidence of stroke, cardiovascular disease and CKD 
between white and black veterans. These results suggest that diabetes care received in the 
VA healthcare organization may potentially mitigate age or racial discordances in clinical 
outcomes that were reported based on the community patient care analyses [27, 37].
Our study is notable for its large sample size and for its representativeness of veterans from 
across the entire US. To the best of our knowledge, it is also the first study to ascertain the 
combined association of abnormal glycemic and hypertension levels on mortality and 
morbidity in diabetes patients from an unselected population enrolled in a large healthcare 
system. Several limitations of our study should be acknowledged. This being an 
observational study, only associations, but no cause-effect relationships can be established 
from it. Our cohort consisted of mostly men; hence, the findings may not be generalizable to 
women. We used multivariable adjusted analyses, but the presence of residual confounders 
cannot be excluded. In addition, not all veterans may have received all their health care in 
VA facilities resulting in missing events. We assessed association with observed levels of 
A1c and SBP, but we cannot ascertain if such levels were due to therapeutic interventions, or 
other factors such as acute or chronic illnesses. Finally, we do not have information about 
cause specific mortality.
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Perspectives
Among patients with diabetes and normal renal function, abnormally elevated systolic blood 
pressure was associated with further increase in the risk of all-cause mortality and incidence 
of nonfatal cardiovascular outcomes independent of glycemic control. Conversely, higher 
A1c levels are associated with higher risk of mortality and vascular events independent of 
SBP levels. Our findings suggest that patients with diabetes may derive additional clinical 
benefits from control of both hyperglycemia and hypertension, if proven so in clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow chart of patients’ selection
Gosmanov et al. Page 11
J Hypertens. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Associations of systolic blood pressure and A1c categories with the risk of death from any 
cause.
The effects of the categories on the mortality risks were estimated from Cox proportional 
hazards models. Risk estimates were adjusted for the following factors at baseline: age, 
gender, race/ethnicity, baseline eGFR, various socio-economic parameters, service 
connection, adherence to medical interventions, comorbidities, body mass index and statin 
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treatment. The adjusted hazard ratios are compared to the reference category of systolic 
blood pressure of 120–139mmHg and A1c of 6.5–7.0% taken as 1.0.
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Figure 3. 
Associations of blood pressure and A1c categories with the risk of cardiovascular disease 
(panel A), stroke (panel B) and chronic kidney disease (panel C).
The effects of the categories on the mortality risks were estimated from Cox proportional 
hazards models. Risk estimates were adjusted for the following factors at baseline: age, 
gender, race/ethnicity, baseline eGFR, various socio-economic parameters, service 
connection, adherence to medical interventions, comorbidities, body mass index and statin 
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treatment. The adjusted hazard ratios are compared to the reference category of systolic 
blood pressure of 120–139mmHg and A1c of 6.5–7.0% taken as 1.0.
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